J&J Says In-Development Blood-Cancer Treatment Shows Promise

By Connor HartJohnson & Johnson released data from a late-stage study of its treatment for certain blood cancers, which showed sustained disease control and survival.The drugmaker on Wednesday said its treatment--a combination of Tecvayli and Darzalex Faspro--significantly improved overall survival…